Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

Summary

This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.

Timeline

Start

2026-04-01

Primary completion

2027-12-30

Completion

2028-06-30

Drugs

Indications